HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.

AbstractOBJECTIVE:
Antipsychotics are effective in treating schizophrenia symptoms. However, the use of clozapine and olanzapine in particular are associated with significant weight gain. Mouse and human studies suggest that the protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene may be involved in energy metabolism, and there is evidence that it is associated with clozapine's effects on triglyceride levels. We aimed at assessing PRKAR2B's role in antipsychotic-induced weight gain in schizophrenia patients.
METHODS:
DNA samples from adult schizophrenia or schizoaffective disorder patients of mixed ancestry were genotyped, and weight gain was assessed. We analyzed 16 tag single-nucleotide polymorphisms across the PRKAR2B gene in a Caucasian subset treated either with clozapine or olanzapine (N = 99). Linear regression based on an additive model was performed with the inclusion of relevant covariates.
RESULTS:
Normalized per cent weight change was analyzed, revealing that patients with the minor allele at rs9656135 had a mean weight increase of 4.1%, whereas patients without this allele had an increase of 3.4%. This association is not significant after correcting for multiple testing.
CONCLUSIONS:
Because of limited power, PRKAR2B's role in antipsychotic-induced weight gain is unclear, but biological evidence suggests that PRKAR2B may be involved. Further research in larger sample sizes is warranted.
AuthorsSarah A Gagliano, Arun K Tiwari, Natalie Freeman, Jeffrey A Lieberman, Herbert Y Meltzer, James L Kennedy, Jo Knight, Daniel J Müller
JournalHuman psychopharmacology (Hum Psychopharmacol) Vol. 29 Issue 4 Pg. 330-5 (Jul 2014) ISSN: 1099-1077 [Electronic] England
PMID24737441 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 John Wiley & Sons, Ltd.
Chemical References
  • Antipsychotic Agents
  • Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit
  • PRKAR2B protein, human
  • Benzodiazepines
  • Clozapine
  • Olanzapine
Topics
  • Adolescent
  • Adult
  • Aged
  • Alleles
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Benzodiazepines (adverse effects, therapeutic use)
  • Clozapine (adverse effects, therapeutic use)
  • Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit (genetics)
  • Female
  • Genetic Predisposition to Disease
  • Genotyping Techniques
  • Humans
  • Linkage Disequilibrium
  • Male
  • Middle Aged
  • Olanzapine
  • Polymorphism, Single Nucleotide
  • Psychotic Disorders (drug therapy, genetics)
  • Schizophrenia (drug therapy, genetics)
  • Weight Gain (drug effects, genetics)
  • White People (genetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: